Generation of Fel d 1 chain 2 genome-edited cats by CRISPR-Cas9 systemopen access
- Authors
- Lee, Sang Ryeul; Lee, Kyung-Lim; Song, Seok-Hwan; Joo, Myeong-Don; Lee, Seo-Hyun; Kang, Ji-Su; Kang, Seon-Min; Idrees, Muhammad; Kim, Jae-Wook; Kong, Il-Keun
- Issue Date
- Feb-2024
- Publisher
- Nature Research
- Keywords
- Allergen; CH2; CRISPR-Cas9; Fel d 1; Genome-edited cats; Hypoallergenic cats
- Citation
- Scientific Reports, v.14, no.1
- Indexed
- SCIE
SCOPUS
- Journal Title
- Scientific Reports
- Volume
- 14
- Number
- 1
- URI
- https://scholarworks.gnu.ac.kr/handle/sw.gnu/69975
- DOI
- 10.1038/s41598-024-55464-0
- ISSN
- 2045-2322
- Abstract
- Allergens from domestic cats (Felis catus) cause allergy-related health problems worldwide. Fel d 1 is a major allergen that causes severe allergic reactions in humans, including rhinitis, conjunctivitis, and life-threatening asthma. Therefore, patients with cat allergies anticipate hypoallergenic cats. We successfully generated Fel d 1 chain 2 (CH2) genome-edited cats using the CRISPR-Cas9 system in this study. T7 endonuclease 1 assay and Sanger sequencing were used to confirm the mutation in CH2 genome-edited cats. Fel d 1 level in CH2 genome-edited cats were assessed by enzyme-linked immunosorbent assay (ELISA). Remarkably, ELISA showed that the level of Fel d 1 in the CH2 homozygous genome-edited cat (Name: Alsik) was extremely low compared with that in wild type domestic cats and could be hypoallergenic cats. Additionally, we successfully cloned the CH2 homozygous genome-edited cat using cytoplasm injection clone technology. The cloned CH2 homozygous genome-edited cat was verified using microsatellite analysis. Creating hypoallergenic cats using the CRISPR-Cas9 system is a significant step forward because these cats can safely approach allergic patients. © The Author(s) 2024.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 자연과학대학 > Division of Life Sciences > Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.